Short answer
Larimar Therapeutics, Inc. (LRMR) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Rolling BLA submission initiated with FDA for accelerated approval of nomlabofusp.
Larimar Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Rolling BLA submission initiated with FDA for accelerated approval of nomlabofusp
- Regulatory milestone advances nomlabofusp toward potential approval for Friedreich’s ataxia
- Positive long-term open-label data reported in adolescent and adult patients
- Data cover daily subcutaneous injections, supporting continued clinical development
- Investor presentation and conference call scheduled for June 29, 2026
Item EX-99.1 · Exhibit EX-99.1
- FDA alignment supports rolling BLA submission for accelerated approval, with first module filed and remaining modules expected in 2H 2026
- Skin FXN exceeded 8.2 pg/µg in 100% of participants at 12 and 18 months, supporting FXN as a potential surrogate endpoint
- Clinical outcomes improved at 1 year versus FACOMS worsening, including mFARS improvement of 1.0 point versus 1.6-point deterioration
- Anaphylaxis occurred in 10 of 41 participants, including one without prior nomlabofusp exposure, creating a key safety and regulatory risk
- Phase 3 initiation planned for Q3 2026, with mid-2027 launch targeted if approved
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Larimar Therapeutics, Inc. 8-K filings
Get the next LRMR 8-K as it lands
Follow LRMR for push alerts, or ask the research agent what this filing means.